The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
Murlidhar Rajagopalan,1 Sunil Dogra,2 Abir Saraswat,3 Sachin Varma,4 Pravin Banodkar5 1Department of Dermatology, Apollo Hospitals, Chennai, Tamilnadu, India; 2Department of Dermatology, Venereology & Leprology, PGIMER, Chandigarh, India; 3Indushree Skin Clinic, Lucknow, Uttar Pradesh, India; 4S...
Guardado en:
Autores principales: | Rajagopalan M, Dogra S, Saraswat A, Varma S, Banodkar P |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fb3c2d3ec0324f159678836bed946a13 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Psoriasis In Patients With Active Lung Cancer: Is Apremilast a Safe Option?
por: Zoe Apalla, et al.
Publicado: (2019) -
Effectiveness of IL-23 Inhibitor Guselkumab in Real-World Chinese Patients with Psoriasis During a 20-Week Period
por: Chan Y, et al.
Publicado: (2021) -
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
por: Riccardo G. Borroni, et al.
Publicado: (2021) -
Assessment and monitoring of biologic drug adverse events in patients with psoriasis
por: Hanley T, et al.
Publicado: (2016) -
Modification of Apremilast from Pills to Aerosol a Future Concept
por: Paul Zarogoulidis, et al.
Publicado: (2021)